PCR Cycle Threshold Arguments and WHO Information Notices
WHO Information Notice 2020/05 instructs PCR users to follow manufacturer IFUs, correlate discordant results clinically, heed prevalence effects on predictive value, and report Ct to clinicians. WHO diagnostic-testing guidance and CDC/FDA assay IFU doors situate RT-PCR as NAT detection with known limits. Adherent “casedemic” readings treat high-Ct/mass testing as manufacturing cases. Contested/L2 documents both without baptism or sneer.